Advanced Enzyme Technologies Limited released its Integrated Annual Report for FY 2025-26, presenting a comprehensive overview of its financial performance, business operations, sustainability initiatives, and governance structure. The report covers the financial year ended March 31, 2026, and includes both standalone and consolidated financial statements audited by MSKA & Associates LLP.

Financial Performance

The company delivered strong consolidated financial results for FY26. Revenue from operations rose 17% to ₹7,458 million from ₹6,369 million in FY25, with international sales of ₹3,731 million (up 8%) and domestic sales of ₹3,727 million (up 28%), each contributing 50% to total revenue. On a standalone basis, revenue from operations grew 29% to ₹4,528 million from ₹3,514 million in FY25.

The following table summarises key consolidated financial metrics:

Standalone profitability also improved markedly. EBITDA stood at ₹1,104 million (24%) versus ₹706 million (20%) in FY25. Standalone PAT increased 29% to ₹1,318 million from ₹1,024 million. Other income for FY26 was ₹348 million compared to ₹330 million in FY25, while depreciation and amortisation stood at ₹401 million versus ₹365 million in FY25. Finance costs declined to ₹26 million from ₹35 million. Return on Equity was 11% in FY26 compared to 10% in FY25.

Key Financial Ratios

Business-wise Performance

The Human Nutrition vertical remained the largest revenue contributor at ₹4,674 million, reflecting 15% year-on-year growth. Within this segment, Serratiopeptidase contributed 23% to consolidated revenue with sales of ₹1,732 million, up from ₹1,193 million in the prior year. Consolidated probiotic revenues stood at ₹216 million. The Biocatalysts segment reported revenues of ₹247 million versus ₹174 million previously.

The Animal Nutrition vertical delivered revenue of ₹946 million, a 25% year-on-year increase. The Bioprocessing business grew 16% overall. Within it, Food Processing revenues reached ₹967 million (up 19% YoY), while Non-Food Processing revenues were ₹209 million, a marginal growth of 0.2%.

Subsidiary Performance

Dividend and Capital

The Board declared an interim dividend of ₹4 per equity share (face value ₹2 each) for FY26 and recommended a final dividend of ₹1.35 per equity share, subject to shareholder approval at the 37th Annual General Meeting scheduled for July 31, 2026. The paid-up share capital stood at ₹223.85 million as of March 31, 2026, comprising 111,926,800 equity shares.

R&D and Innovation

Consolidated R&D expenditure for FY26 was ₹246 million (3.30% of net sales), compared to ₹248 million (3.86% of net sales) in FY25. On a standalone basis, total R&D expenditure was ₹355.92 million (7.86% of net sales) versus ₹328.39 million (9.34% of net sales) in FY25. The company filed three patent applications and three GRAS dossiers with the US FDA during the year. A new large-scale R&D centre is under development in Nashik, expected to be operational in the latter half of FY 2026-27.

Operations, Sustainability and Governance

Exports accounted for 33.58% of standalone revenues, with the company exporting to 52 countries across five continents. The company operates four plants and two offices nationally. Total energy consumed from renewable sources was 1,471 GJ, with an installed solar capacity of 510 kW. Scope 1 GHG emissions stood at 25,988 tCO2e and Scope 2 at 8,974 tCO2e in FY26. The company recycled 33% of water consumed and reused 337 MT of waste.

The workforce comprised 400 employees and 362 workers at year-end, with women representing 22.25% of total employees. The employee retention rate was 86%. The company spent ₹647 million towards employees during FY26. The Board comprised nine directors as of March 31, 2026, with Mr. Vasant Rathi as Chairman and Non-Executive Director and Mr. Mukund Kabra as Whole-time Director. ICRA assigned [ICRA]AA-(Stable) for long-term fund-based cash credit and [ICRA]A1+ for short-term non-fund based limits.

During FY26, the Board approved collaboration for a group captive wind power project through a Special Purpose Vehicle, with an investment of up to 26% equity stake, to avail wind power of up to 1.9 MW for plants at Sinnar and Pithampur. Advanced Nutrazyme Private Limited was incorporated on July 4, 2025 as a wholly owned subsidiary to expand the company's presence in the nutrition and wellness segment under the WELLFA brand.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE837H01020/32b6ab3b-2453-4420-b4e1-cc3e815ba126.pdf

Advanced Enzyme Technologies Ltd has fixed Friday, July 24, 2026 as the record date for the payment of a final dividend of ₹1.35 per equity share of ₹2 each for the financial year 2025-26. The dividend recommendation is subject to approval by shareholders at the upcoming Annual General Meeting. This payout, if declared, will be paid on or after August 03, 2026, subject to deduction of tax at source.

The 37th Annual General Meeting of the company is scheduled to be held on Friday, July 31, 2026, through Video Conference and Other Audio Visual Means. The record date was fixed in accordance with Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Dates and Dividend Details

The following table outlines the critical dates and purpose of the corporate action:

Shareholders registered in the records of the company on the record date will be eligible to receive the dividend, provided it is approved by the members during the AGM.